South Korea Dravet Syndrome Market: Analyzing the Treatment Landscape, Pipeline Drugs, and Patient Care Evolution
The South Korea Dravet Syndrome Market focuses on the complex landscape of managing this severe, intractable form of epilepsy that begins in infancy, often caused by a mutation in the SCN1A gene. Given the rarity and severity of the condition, the market size is niche but holds immense significance due to the high unmet medical need. Current management involves a combination of anti-epileptic drugs (AEDs), such as stiripentol, clobazam, and valproate, often in polytherapy, to control the frequent, prolonged, and drug-resistant seizures that characterize the syndrome. The primary drivers of market value are the introduction and adoption of specialized, high-cost orphan drugs specifically approved for Dravet Syndrome.